← All trials
NCT06435299
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2025
- Primary completion
- Feb 14, 2026
- Completion date
- Nov 28, 2026
- First posted
- May 30, 2024
- Last posted
- Oct 26, 2024
- Enrollment
- 218
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Western BrittanyLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.